Next-Gen of Biotherapies

Advancing Bromelain-Based Novel Therapies
for Better Standard of Care

Overview

Diversified Portfolio of Advanced Therapies

Our capabilities are well demonstrated in our diversified products and pipeline.

NexoBrid, our commercial orphan biological product for eschar removal of severe thermal burns, is a bromelain-based biological product, containing a sterile mixture of proteolytic enzymes that selectively removes burn eschar within four hours and does not harm surrounding viable tissue. Nexobrid is currently marketed in the European Union as well as in other international markets and is at a registration stage in the U.S. NexoBrid is supported by the U.S. Biomedical Advanced Research and Development Authority (BARDA).

EscharEx, our next-generation bioactive therapy for debridement of chronic and hard-to-heal wounds, is a product candidate in advanced stages of clinical development. In two Phase 2 studies, EscharEx was well-tolerated and has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, with only a few daily applications.

MW005, our topical enzymatic therapy for the treatment of non-melanoma skin cancers, is a clinical-stage product candidate under development.

NexoBrid®

Disruptive Therapy for Burn Care

EscharEx®

Next-gen of Wound Care

MW005

Non-Melanoma Skin Cancers Therapy

Pipeline

Novel Therapies for a Better Standard of Care

  • Product
  • PHASE I
  • PHASE II
  • PHASE III
  • Commercialization

NexoBrid® Eschar removal of deep partial and full thickness burns

Registration Stage in the U.S.

NEXT Expanded access treatment protocol

CIDS Pediatric phase 3 study

EscharEx® Debridement of chronic wounds

ChornEx U.S. Phase 2 adaptive design study

PharmEx Phase 2 pharmacology study

MW005 Non-melanoma skin cancer

Phase I/II study in BCC